Clinipace expects continued success in 2011
As well as carrying out regulatory consulting, biostatistics and functional monitoring, Clinipace said it was awarded contracts to manage various Phase I, II and III clinical trials in multiple therapeutic areas, including nephrology, oncology, cardiovascular and immunology.
Dave Levin, a spokesperson for Clinipace, told Outsourcing-Pharma that last year’s result were “very significant.” He said: “Our continued revenue grows and our ability to sign new clients demonstrates our ability to serve our clients and validates our digital clinical research organisation (dCRO) service delivery model.”
The Research Triangle Park, US-headquartered dCRO said that as a result of its success, its hiring rate grew by 28 per cent to support increased demand for its services.
Employees were added in clinical operations, data management, software engineering and sales and the firm has now revealed plans to hire an additional 30-50 per cent throughout 2011.
Technology drives clinical research
Clinipace claims it is changing the way clinical trials are run by using technology to drive clinical research, which optimises project performance and keeps costs to a minimum.
By adopting a standards-based technology platform, the firm said it offers enhanced communication, productivity and visibility to clinical operations and data management.
Levin said: “Emerging and mid-tier biotechs, pharmaceuticals and device firms really value our technology-amplified services and appreciate the visibility and predictability our approach provides.”
A positive 2011
He went on to say that Clinipace is optimistic about 2011, as the conduct of clinical trials for the pharma and biotech segment remains a fast growing market.
“With big pharma divesting research and development (R&D) and partnering with smaller, earlier stage firms, we see more opportunity to serve these firms,” said Levin. “Our service delivery and infrastructure is very well suited to support this strategic shift.”
The dCRO claims to have seen a rebound in new clinical trial starts in 2010 after a minor dip in 2009. Based on such improvements, the firm expects to see growth in new client starts this year among emerging and mid-tier firms.
This year, Clinipace plans to expand its oncology, CNS and immunology drug trials, while continuing to invest in services to medical device firms.
